Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$112.50 USD

112.50
643,774

+0.54 (0.48%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $112.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific Grows on Innovation, Buyouts Amid Woes

While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

    Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

    Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.

      HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

      HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.

        Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN

        The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.

          Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness

          Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.

            Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife

            Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.

              Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level

              With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.

                Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks

                In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.

                  Hologic (HOLX) Launches Brevera, Progresses in Breast Health

                  Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.

                    Mazor Robotics Hits 52-Week High Through Medtronic Alliance

                    Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.

                      GNC Holdings Gains on New GNC Strength Amid Soft Revenues

                      GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.

                        Haemonetics Grows on Strong Plasma, Blood Center Sluggish

                        Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.

                          Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

                          Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

                            Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm

                            Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.

                              Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

                              Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

                                BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                                BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                  3 Excellent Value Picks as Political Chaos Grips MedTech

                                  In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.

                                    Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group

                                    Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group

                                      VWR Awaits Merger Closure, Stock Upside Potential Limited

                                      VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.

                                        Cooper (COO) Poised to Grow on Specialty Lenses Prospects

                                        Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.

                                          Accuray (ARAY) Grapples With Falling Margin and Product Mix

                                          Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.

                                            Thermo Fisher Acquires Patheon, Boosts Laboratory Products

                                            Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.

                                              Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now

                                              Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.

                                                5 Excellent Value Stocks Based on Low PEG Ratio

                                                While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.

                                                  Intuitive Surgical (ISRG) Well Poised on Procedural Business

                                                  Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.